


Curapath and Iris Biotech Partner to Provide Wider Access to Innovative Excipients for Drug Delivery

PATERNA, VALENCIA, SPAIN, October 2,
2025 /EINPresswire.com/ -- [Curapath](#), a
leading innovator in the design and
manufacturing of polymer and
□□□□□□ □□ □□□□-□□□□ □□□
□□□□□□□□ □□□□□□□□, is proud to
announce a strategic partnership with
[Iris Biotech](#), a global distributor of
specialty reagents for drug
development and delivery. Through
this collaboration, Iris Biotech will offer
a broad selection of Curapath's
proprietary polymers, including
□□□□□□□□□□□□□□, □□□□□□□□□□□□, □□□
formulation, conjugation, encapsulation



Curaphath's polymers are developed and manufactured at its headquarters in Valencia, Spain, and are available in both α - and β -forms. These materials are designed to meet the growing demand for α - and β -cyclodextrins, α - and β -cyclodextrin derivatives, and α - and β -cyclodextrin derivatives in modern drug delivery systems, including lipid nanoparticles (LNPs), polymeric systems, and conjugates like polymer-drug systems or antibody drug conjugates (ADCs).

Among the highlights of this partnership is the availability of [poly\(2-dimethylaminoethyl methacrylate\) \(PDMAEMA\)](#), versatile polymers classes offering a non-immunogenic [poly\(2-dimethylaminoethyl methacrylate\) \(PDMAEMA\)](#) [poly\(2-dimethylaminoethyl methacrylate\) \(PDMAEMA\)](#) conferring stability, shielding and stealth functionalities to nanoformulations. These polymers provide comparable efficacy to PEGylated systems while addressing concerns related to PEG-associated immunogenicity and hypersensitivity reactions.

[illegible]

With this partnership, Iris Biotech strengthens its portfolio of cutting-edge materials for drug delivery, offering researchers a reliable source of high-quality polymers tailored for the evolving needs of pharmaceutical innovation.

For more information, please visit our website: <https://iris-biotech.de/global/drug-delivery.html>

For more information, please visit our website:

Iris Biotech is providing high quality products for the fields peptide and nucleic acid synthesis, linkerology®, drug delivery, and life sciences in flexible quantities from research scale to commercial production, for academia as well as industry.

Besides the broad portfolio from standard to exotic, Iris Biotech has the know-how and facilities to manufacture the compound of choice based on a Custom Synthesis.

All the services are rounded off by a strong and competent personnel customer support. Iris Biotech is in continuous exchange with scientists all around the world to gather ideas and be ahead regarding technologies and innovations true to the slogan Empowering Peptide Innovation.

Learn more at: <https://iris-biotech.de/es/home>

For more information, please visit our website:

Curapath is a science-driven CDMO specializing in the design, development, and GMP manufacturing of advanced drug delivery systems. We support biopharma companies from early R&D through to commercial production, enabling innovation across every stage. With a strong expertise in nanoencapsulation and non-viral gene delivery, we offer polymer and lipid-based nanoparticles tailored for a wide variety of payloads. From excipient synthesis to drug product formulation, our flexible service model and proprietary technologies ensure a seamless path to the clinic. Committed to quality, innovation, and collaboration, we help bring next-generation therapies to market faster.

Learn more at www.curapath.com

Curapath

Curapath

+34 963 76 90 80

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/852337766>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.